Tempus ECG-AF vs Viz RV/LV
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your primary objective is to proactively identify patients aged 65 or older at an increased risk of developing new-onset atrial fibrillation within the next 12 months. This tool is ideal for integrating into routine cardiology, geriatrics, or internal medicine workflows to leverage standard 12-lead ECGs for earlier risk stratification and follow-up planning.
View Tempus ECG-AF →Choose Viz RV/LV if…
Choose Viz RV/LV if you require rapid, automated right and left ventricular diameter measurements from CTPA scans for acute pulmonary embolism (PE) risk stratification. This solution is best suited for emergency medicine, pulmonology, or radiology departments where quick, accurate assessment of PE severity and seamless care team coordination are critical for managing patients with suspected PE.
View Viz RV/LV →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | Viz RV/LV |
|---|---|---|
| Pricing | Contact vendor | Unknown |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | Cloud-based |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Viz RV/LVViz RV/LV (Tool B) is cloud-based and emphasizes mobile access, AI-powered alerts, and a HIPAA-compliant communication platform for care coordination, suggesting a highly interactive and accessible user experience. Tempus ECG-AF (Tool A) integrates into existing facility systems, which is good for workflow, but lacks the explicit mobile and communication features highlighted by Viz.ai.
Clinical Value
TieBoth tools are FDA-cleared and address critical clinical needs. Tempus ECG-AF (Tool A) provides early identification of AF risk, a proactive measure for a chronic condition. Viz RV/LV (Tool B) offers rapid risk stratification for acute pulmonary embolism, a time-sensitive and life-threatening condition. Both provide crucial, actionable insights for clinical decision-making within their respective domains.
Pricing & Value
Tempus ECG-AFTempus ECG-AF (Tool A) provides clear financial transparency by stating CMS reimbursement availability (CPT 0764T and CPT 0765T) and a Medicare rate of $128.90, effective January 1, 2025. Viz RV/LV (Tool B) does not publicly disclose its pricing, making it difficult for healthcare providers to assess its immediate financial value without direct vendor engagement.
Enterprise Readiness
Viz RV/LVBoth tools are FDA-cleared, HIPAA compliant, and have BAAs, indicating strong foundational readiness. Viz RV/LV (Tool B) is cloud-based and presented as a 'seamless component of the Viz PE Solution,' suggesting a comprehensive, scalable platform approach for enterprise deployment, particularly in acute care workflows. Tempus ECG-AF (Tool A) integrates into existing systems, which is also valuable, but Viz.ai's broader solution integration and cloud-native approach offer a slight edge in modern enterprise scalability and deployment.
Innovation
Viz RV/LVWhile Tempus ECG-AF (Tool A) innovates by predicting future AF risk from standard ECGs, Viz RV/LV (Tool B) combines automated critical measurements for acute PE risk stratification with real-time AI-powered alerts, mobile viewing, and a communication platform for care coordination. This integration of AI analysis with immediate, collaborative workflow tools for acute conditions represents a broader and more impactful innovation in clinical practice.
Support & Docs
Viz RV/LVViz.ai (Tool B) demonstrates more comprehensive and transparent support, offering 24/7/365 urgent phone support, a dedicated Help Center, Knowledge Base, and a Trust Center with detailed security and privacy documentation. Tempus AI (Tool A) provides general customer support via email and local reps, and mentions a 'Tempus Hub' and API documentation, but lacks the explicit, readily available, and extensive support resources highlighted by Viz.ai.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | Viz RV/LV |
|---|---|---|
| Tool Name | Tempus ECG-AF | Viz RV/LV |
| Company | Tempus AI, Inc. | Viz.ai |
| Description | Tempus ECG-AF is an FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. | Viz RV/LV by Viz.ai is an FDA-cleared AI algorithm that automates right and left ventricular diameter measurements from CTPA scans, providing a crucial RV/LV ratio for rapid pulmonary embolism risk stratification and enhanced care coordination within the Viz PE Solution. |
| Key Functionality | AI-based algorithm for 12-lead ECG analysis; Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months. | Automated Right Ventricle (RV) to Left Ventricle (LV) ratio measurement; Analysis of volumetric CTPA acquisitions; AI algorithm for identification and measurement of heart ventricles. |
| Target Patient Population/Input Data | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery; analyzes 12-lead ECG recordings. | Volumetric CTPA acquisitions for suspected pulmonary embolism detection. |
| Specialties | Cardiology, Geriatrics, Internal Medicine | Emergency Medicine, Pulmonology, Radiology |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and Viz RV/LV.